The replacement of malfunctioning heart valves with prosthetic counterparts has been an accepted routine clinical procedure for over twenty years. Hufnagel (1951) showed that manmade materials could be tolerated in the blood stream and his caged-ball prosthesis placed in the descending aorta was able to function in many patients for reasonably long periods. Total or partial valve replacement became a viable therapeutic option subsequent to the development of extracorporeal circulation, as described by Gibbon (1954) .
Mechanical valves
The use of a caged-ball valve in the descending aorta became obsolete with the development of what today is still referred to as the Starr-Edwards ball and cage valve, as illustrated in Figure I . In concept it was similar to the original Hufnagel valve but was designed to be inserted in place of the excised diseased natural valve. This form of intracardiac valve replacement in the mitral position was reported by Starr (1960) and for aortic and multiple valve replacements by Cartwright et al. (1962) . Since 1962, the Starr-Edwards valve has undergone many modifications in order to improve its performance in terms of reduced haemolysis and thromboembolic complications. However, the changes have involved materials and techniques of construction and have not altered the overall concept of the valve design in any way. Attempts to reduce the overall height of the valve by using a disc occluder in a flattened cage were not successful and the still popular current models continue to use a spherical occluder. Other manufacturers have produced variations of the ball and cage valve, notably the Smeloff-Cutter valve and the Magovern prosthesis. In the case of the former, the ball is slightly smaller than the orifice. A subcage on the proximal side of the valve retains the ball in the closed position with its equator in the plane of the sewing ring. A small clearance around the ball ensures easy passage of the ball into the orifice. This clearance also gives rise to a mild regurgitation which was felt, though not proven, to be beneficial in preventing thrombus formation. The Magovern valve is a standard ball and cage format which incorporates two rows of interlocking mechanical teeth around the orifice ring. These teeth are used for inserting the valve and are activated by removing a special valve holder once the valve has been correctly located in the prepared tissue annulus. Neither of these two modified ball and cage valves has attained significant popularity. Indeed, in the case of the Magovern valve, the potential hazard from dislocation from a calcific annulus due to imperfect placement was soon observed. This valve is no longer in use.
Many other variations of caged occ1uder valves could be listed but none have been able to displace the Starr-Edwards as the preferred valve in this category. Even after twenty years of valve development, the ball and cage format remains a valve of choice amongst some surgeons. However, it is no longer the most popular mechanical valve, having been superseded, to a large extent, by tilting disc or hinged leaflet valves. This latter group of valves, two of which are shown in Figure 1 , o.vercomes two major drawbacks to the ball valve, namely, large profile height and excessive occluder-induced turbulence in the flow through and distal to the valve. As already noted, attempts to obviate the former disadvantage of the ball valve were made using a caged disc format. In 1965, the Kay-Shiley caged disc valve achieved some popularity but was soon found to be deficient from the point of view of disc wear and systemic embolism, as discussed by Hughes & Carey (1969) .
The most significant developments in mechanical valve design occurred in 1969 and 1970 with the introduction of the Bjork-Shiley and Lillehei-Kaster tilting disc valves. Both prostheses involve the concept of a 'free' floating disc which, in the open position, tilts to an angle depending on the design of the disc retaining struts. In the original Bjork-Shiley valve, the angle of tilt was 60°for the aortic, and 50°for the mitral model. The Lillehei-Kaster valve has a greater angle of tilt of 80°, but in the closed position is pre-inclined to the valve orifice plane by an angle of 18°. In both cases the closed valve configuration permits the occluder to fit into the circumference of the inflow ring with virtually no overlap, thus reducing mechanical damage to erythrocytes. A small amount of regurgitation backflow induces a 'washing out' effect of 'debris' and platelets and theoretically reduces the incidence of thromboemboli (cf. Smeloff-Cutter valve description).
The obvious advantage of the tilting disc valve is that in the open position it acts like an aerofoil in the blood flowing through the valve, and induced flow disturbance is substantially less than that obtained with a ball occluder. Although the original Bjork-Shiley valve employed a 'Delrin' occluder, all present-day tilting disc valves use pyrolitic carbon for this component. It should also be noted that the 'free' floating disc can rotate during normal function, thus preventing excessive contact wear from the retaining components on one particular part of the disc.
Tilting disc valves remain popular (cf. Figure 3 ) although central orifice tissue valves, as discussed in the section which follows, are gaining in usage. Various improvements to this form of mechanical valve have been developed but have tended to concentrate on alterations either to the disc geometry as in the Bjork-Shiley Concavo-Convex design, or to the disc retaining system as with the Omniscience valve.
Perhaps the most interesting development has been that of the bi-leaflet pyrolitic carbon valve produced by St Jude Medical Inc. This design incorporates two semicircular hinged pyrolitic carbon occluders which in the open position provide minimal disturbance to flow. Details of in vitro studies on this valve were published by Emery & Nicoloff (1979) and early clinical evaluation of its performance by Emery et al. (1979) . The evidence provided in these papers indicates some promise for this design of mechanical valve.
The informed reader will realize that this section on mechanical valves has highlighted a relatively small number of the many various forms which have been made. However, those that have been included are either the most commonly used, or are those which have made notable contributions to mechanical valve design. In a later section the methods used to test valves in the laboratory are discussed. The lack of standardization of such test procedures inevitably makes it difficult to obtain genuinely comparative data on the various different valves..Sadly, in vitro performance differences amongst the valves are often relatively small, and claims made for new designs may lack scientific integrity in the face of commercial necessity. However, the majority of mechanical valves do offer patients reasonable hope for several years of event-free survival even though they bear no morphological comparison to natural valves. In the following section the development of 'tissue' valves which are similar or, indeed, identical to natural valves, is discussed.
Tissue valves
One major disadvantage with the use of mechanical valves is the need for continuous anticoagulation therapy to minimize the risk of thrombosis and thromboembolic complications. Furthermore, the haemodynamic function of even the best types of mechanical valves differs significantly from that of normal heart valves. An obvious step, therefore, in the development of heart valve substitutes was the application of naturallyoccurring heart valves. This was the basis of the approach to the use of treated human aortic valves removed from cadavers for implantation in place of their diseased counterparts.
The first of these procedures was carried out by Ross in 1962, and the overall results so far have been satisfactory (Wain et al. 1980) . This is, perhaps, not surprising since the . replacement valve is optimum both from the point of view of structure and function ..In the open position these valves provide unobstructed central orifice flow and also have the ability to respond to deformations induced by the surrounding anatomical structure. As a result, such substitutes are less damaging to the blood when compared with the rigid mechanical valve. The main problem with these cadaveric allografts, as far as may be ascertained, is that they are no longer living tissue and therefore lack that unique quality of cellular regeneration typical of normal living systems. This makes them more vulnerable to longterm damage.
An alternative approach is to transplant the patient's own pulmonary valve into the aortic position. This is possible, since not only are the two valves of similar morphology, but also because reasonable myocardial function can still obtain in the absence of the pulmonary valve. This operation was also first carried out by Ross, in 1967 , and his subsequent study of 176 patients followed up over 13 years showed that such transplants continued to be viable in their new position with no apparent degeneration (see Wain et al. 1980) . This transplantation technique is, however, limited in that it can only be applied to one site.
The next stage in the development of tissue valve substitutes was the use of autologous fascia lata either as free or frame-mounted leaflets. The former approach for aortic valve replacement was reported by Senning in 1966, and details of a frame-mounted technique were published by Ionescu & Ross in 1969. The approach combined the more natural leaflet format with a readily available living autologous tissue. Although early results seemed encouraging, Senning expressed his own doubt on the value of his approach in 1971, and by 1978 fascia lata was no longer used in either of the above, or any other, form of valve replacement. The failure of this technique was due to the inadequate strength of this tissue when subjected to long-term cylic stressing in the heart. This situation might have been avoided if adequate analysis of the mechanical behaviour of fascia lata had been undertaken.
In parallel with the work on fascia lata valves, alternative forms of tissue leaflet valves were being developed. In these designs, however, more emphasis was placed on optimum performance characteristics than on the use of living tissue. In all cases the configuration involved a three-leaflet format which was maintained by the use of a suitably designed mounting frame. It was realized that naturally-occurring animal tissues, if used in an untreated form, would be rejected by the host. Consequently, a method of chemical treatment had to be found which obviated this antigenic response but did not degrade the mechanical strength of the tissue.
Formaldehyde has been used by histologists for many years to arrest autolysis and 'fix' tissue in the state in which it is removed. It had been used to preserve biological tissues in cardiac surgery but, unfortunately, was found to produce shrinkage and also increase the 'stiffness' of the resulting material. For these reasons, formaldehyde was not considered ideal as a method of tissue treatment.
.Glutaraldehyde is another histological fixative which has been used especially for preserving fine detail for electron microscopy. It is also used as a tanning agent by the leather industry. In addition to arresting autolysis, glutaraldehyde produces a more flexible material than does formaldehyde, with improved strength characteristics due to increased collagen cross-linking. Glutaraldehyde has the additional ability of reducing the antigenicity of xenograft tissue to a level at which it can be implanted into the heart without significant immunological reaction.
In 1969, Kaiser et al. described a valve substitute using an explanted glutaraldehydetreated porcine aortic valve which was mounted on to a rigid support frame. Following a modification described by Reis et al. (1971) , in which the rigid frame was replaced by a frame having a rigid base ring with flexible posts, this valve became commercially available as the Hancock Porcine Xenograft. It remains. one of the two most popular valve substitutes of this type, the other being the Carpentier-Edwards Bioprosthesis introduced commercially by Edwards Laboratories in 1976. This latter valve uses a totally flexible support frame.
In this type of prosthesis, the use of the intact biologically-formed valve obviates the need to manufacture individual valve cusps. Whilst this has the obvious advantage of reduced complexity of construction, it does require a facility for harvesting an adequate quantity of valves so that an appropriate range of valve sizes of suitable quality can be made available. This latter problem did not occur in the production of the three-leaflet calf pericardium valve developed by Ionescu et al. (1971) . The construction of this valve involves the moulding of fresh tissue to a tricuspid configuration around a support frame and, whilst held in this position, the tissue is treated with glutaraldehyde solution. The valve, marketed in 1976 as the Ionescu-Shiley Pericardial Xenograft, is currently the most popular valve of its type. Examples of a mounted porcine valve and a bovine pericardium valve are shown in Figure 2 . Clinical results so far obtained with tissue valves indicate their superiority to Figure 2: LEFT, a Carpentier-Edwards Bioprosthesis (porcine); RIGHT, an Ionescu-Shiley Pericardia) Xenograft mechanical valves with respect to a lower incidence of thromboembolic complications and more natural haemodynamic characterisitcs. For these reasons the use of tissue valves has increased significantly, as reflected in the data submitted to the Multicentre Valve Trial. This latter information is shown in Figure 3 for the period 1974-1982.
It is interesting to note that, as is the case with mechanical valves, all the popular tissue prostheses are manufactured in the United States of America and, until recently, there was no competition from the United Kingdom in this field. However, the first commerciallyavailable British tissue valve, the Wessex Porcine Bioprosthesis manufactured by Wessex Medical Laboratories Limited, has recently begun a series of clinical trials having successfully completed both laboratory evaluation and animal trials.
Despite the generally excellent haemodynamic performance of tissue valves, recent reports on clinical experience with these valves increasingly indicate time-dependent structural changes leading to failure and subsequent replacement. Amongst the first of such reports were those. by Ashraf & Bloor (1978) , Housman et al. (1978) and Broom (1978) . Such problems have not been eliminated by the glutaraldehyde tanning methods so far employed, and it is not easy to see how these drawbacks are to be overcome unless either living autologous tissue is used or the original structure of the collagen and elastin are chemically enhanced. On the latter point there is, as yet, much room for further work. For instance, the fixing of calf pericardium under tension during the moulding of the valve cusps will inevitably produce 'locked-in' stresses during fixation, thus changing the mechanical properties of the tissue (Reece et al. 1982) . A valve configuration which does not involve fixation moulding of the cusps would be advantageous.
The design of a new pericardium valve, presently being developed by Black et al. (1982) in . Sheffield, allows the valve cusps to be formed using fully fixed, unstressed pericardium.
Furthermore, this valve is specifically designed for the mitral position and is consequently of a bicuspid form. The design also incorporates a differentially flexible frame. This allows the base ring to deform from circular in diastole to an approximate D-shape in systole, thus reproducing the physiological behaviour of the normal mitral valve annulus during the cardiac cycle. ..- 1974 1975 1976 1977 1978 1979 1980 1981 year ' ,. As with mechanical valves, much useful information can be obtained from in vitro studies such as those described in a later section. In particular, accelerated fatigue systems can yield valuable information on the possible long-term durability of this type of valve in relation to mechanical stressing.
Mechanical versus tissue valves
It will be obvious from the foregoing sections that the different types of heart valve substitutes currently available have individual advantages and disadvantages. Certainly, none of the present prostheses could be regarded as ideal, or even optimum,replacements for natural valves. To identify in detail the good and bad points of each valve would require a publication in its own right and would not add significantly to the value of this present paper. However, in general terms, valve type advantages and disadvantages can be classified as shown in Table I . From this table it is clear that surgeons are faced with a difficult situation when deciding on the most appropriate valve type for any particular patient. In many cases a surgeon will tend to use one particular valve type almost to the total exclusion of any other, This does not imply a narrow outlook on the part of the surgeon, but rather a natural scepticism in relation to what is often clinically unsubstantiated information provided by various manufacturers regarding new valve products, At the present time there is no recognized 'neutral' valve evaluation centre in the United Kingdom or in any other country. Individual research groups do undertake comparative in Table I 
. Advantages and disadvantages of mechanical and tissue valves

Valve type
Advantages Disadvantages For the present, the surgeon has to make his own assessment of the potential advantages and disadvantages of any particular design. Whilst the apparent long-term durability of mechanical valves is immediately attractive, problems of maintaining large and increasing numbers of patients on optimum anticoagulation therapy can lead to logistic difficulties. Incidence of significant levels of haemolysis due to mechanical damage can also militate against their extensive use by many surgeons.
As already noted, the ultimate assessment of any valve can only be achieved through longterm clinical implantation and follow up. Individual surgeons maintain such recordson their own cases. However, it is obvious that a survey involving many units offers a greater opportunity for collecting, not only much larger numbers, but also for obtaining data on a wider range of valve types. Such a trial was initiated in 1974 under the auspices of the Cardiac Surgical Research Club. At present there are over 3000 individual valve implants recorded on computer, covering 37 valve models. Analysis of this Multicentre Valve Trial information was used to provide the data given in Figure 3 and Tables 2 and 3. It can be seen from Figure 3 that approximately 60% of the valve implants recorded by the Trial in each of the last three years involved tissue valves. This result is, of course, dependent on the preferences of the 29 surgeons participating in the Trial, but is a reasonable guide to the overall picture in the United Kingdom at the present time.
The data given in Tables 2 and 3 represent the actuarial probabilities of 'patient survival' and 'freedom from valve complications' respectively. In the case of patient survival, the most obvious feature is the sudden drop in survival to 61.5% after 7 years for those patients. with a Hancock porcine mitral prosthesis. Although the results for 6 to 7 years follow up are, as yet, incomplete for some of the other valves listed in Table 2 , those which have gone beyond 5 years do not indicate such a dramatic fall.
A similar phenomenon is observed from the figures defining freedom from valve complications. In this case the valve showing the most severe drop is the Starr-Edwards 1260 aortic model at a value of 42.5% after 6 years, with its mitral counterpart, the 6120 Table 2 . Actuarial values of probabilities of patient survival after valve replacement: Multicentre Valve Trial 1974-82 (follow-up data for years 6 to 8 not yet complete) Table 3 has, as yet, dropped below 70% in terms of freedom from valve complications. These latter differences in valve performance, which relate to their clinical use, are unlikely to be predicted from in vitro laboratory tests such as those discussed in the section which follows.
In vitro testing of heart valve substitutes
Although the ultimate assessment of prosthetic valve performance must come from animal and, more importantly, clinical implantation, the initial evaluation of any new design can be obtained from appropriate laboratory tests. There are several areas where in vitro testing can yield valuable information for both the cardiac surgeon and the valve designer. However, if such studies are to be useful from a 'clinical' point of view, the experiments must be performed under carefully controlled conditions and their relevance to the clinical situation must be clear. Many sophisticated laboratory studies have been undertaken which provided comparative evaluations of valve substitutes but did not give any insight into the valves' in vivo performances. The interpretation of such in vitro test results must be approached with caution by recognizing their limitations when extrapolated to the in vivo situation .
Haemodynamic testing or, more correctly, hydrodynamic testing is a useful indicator of the fluid mechanical performance of a valve. Steady flow studies are by far the simplest to perform since they do not involve the need to simulate the pulsatile nature of the cardiac cycle. However, it is important that the valve test section of the flow circuit be designed so as to reproduce the anatomy of the biological flow passages. Several studies, including those by Kramer et al. (1975) , Naumann & Kramer (1970) and Bellhouse & Bellhouse (1969) , have shown that flow passage geometry has a profound effect on the valve's performance.
The pressure drop across a valve can be measured over a range of flow rates, from which various parameters can be derived such as 'effective orifice area' and 'discharge coefficient'. This simple test procedure can also highlight defects in the opening characteristics of a tissue valve, for example, excessive leaflet stiffness or leaflet flutter, either of which may be detrimental to its subsequent in vivo performance. The sites at which pressure measurements are made both upstream and downstream from the valve must be standardized. In the case of aortic valve substitutes, several downstream pressure measurements must be made at different axial locations, since, due to the phenomenon of 'pressure recovery', an axial variation in the measured pressure drop will obtain. This phenomenon is well known to fluid mechanicists from the study of flow through constricting orifices. It can be explained by the interchanges between kinetic and potential energy of the fluid which occur due to the restrictive nature of the orifice. An illustration of this effect on the pressure drop across heart valve substitutes is shown in Figure 4 . This figure shows plots of the axial variation of the measured pressure drop for a series of 23 mm tissue annulus diameter aortic valve substitutes. The results have been grouped according to the type of valve, that is, mechanical or biological. It is of interest to note that the valves tested form two quite distinct categories, with the pressure drop at any axial location being significantly greater overall for the tissue valves. However, it must be stressed that these data cannot be used to extrapolate to the behaviour of other valve sizes.
Whilst steady flow testing provides a useful 'first line' approach to the in vitro assessment of valves, its shortcomings are obvious. Since the normal pulsatile flow of blood is not simulated, valve dynamics cannot be studied, nor can the degree of valvular regurgitation be accurately assessed. In order to investigate valve performance in greater depth a 'pulse duplicator', which accurately simulates the pumping action of the heart, is required. Over the last thirty years many different designs of pulse duplicator have evolved. Although they all have one feature in common, namely a device for producing pulsatile flow through the test valve, the majority of the earlier designs fell short of their goal to simulate the action of the human heart. This, in turn, led to inaccuracies when results from such test systems were unwisely extrapolated to the in vivo situation. For example, the in vitro results of McMillan et al. (1952) suggested that the human aortic valve did not open fully at any time during systole. This was later completely contradicted by studies performed by Padula et al. (1968) on the aortic valve in an actively beating heart, and also by more refined model studies of aortic valve dynamics carried out by Bellhouse & Bellhouse (1969) . Such inaccuracies do not obtain with the newer, more sophisticated pulse duplicators described by Scotten et al. (1979) , Martin et al. (1978) and Reul et al. (1974) .
Pulse duplicator design must of necessity involve a compromise between the need to simulate accurately in vivo behaviour so as to obtain clinically useful data, and the requirement of a system which is practicable for routine laboratory use. The layout of one such system, currently in use in Sheffield, is shown in Figure 5 . This computer-controlled pulse duplicator has taken several years to develop and has been described in more detail by Martin et al. (1981) . The parameters which ha\,e been used to define valve performance during pulsatile flow are many and varied. The most commonly used are pressure drop and regurgitation and, to a lesser extent, power and energy losses through the valve, as well as turbulence measurements. Evaluation of the magnitude of the shear stresses in the blood in the vicinity of artificial valves has been used as a measure of the 'blood damaging' characteristics of the valve. Valve dynamics can also be assessed qualitatively using high speed cinematography with subsequent frame-by-frame analysis. This technique is particularly useful for studying valve deformations during the in vitro cardiac cycle.
In an earlier section reference was made to the concern of surgeons regarding long-term durability of tissue valves. This continues to be one of the major drawbacks of these valves, and currently the only universally-accepted method of evaluating valve durability is by extensive routine clinical use. This has the inherent disadvantage that the assessment of any particular valve, or modified design, is not known for several years, by which time the reasons for failure may well be obscure. Although both mechanical and biological factors can influence valve failure, their individual effects often cannot be separated in the clinical implantation situation. These problems can be partially overcome by accelerated fatigue testing of valves in the laboratory. This technique can usually isolate the mechanical factors which might reduce the long-term durability of any prosthesis. Such test systems are designed to open and close the valve at a rate that is much greater than the average physiological value of around 70 beats/min, and with some equipment can be as high as 1400 cycles/min. In this way, six months' continuous running in the laboratory is 'mechanically' equivalent to ten years' in vivo operation. Varying degrees of success with this approach to valve-fatigue testing have been achieved by a number of researchers, as assessed by comparison of results with observed long-term clinical findings. This aspect of valve testing .has been discussed in detail by Swanson & Clark (1981) . One particular test system is illustrated in Figure 6 . Its principle of operation involves small-amplitude axial oscillations of the test valve at high frequency in a fluid medium. The inertial fluid forces that are produced not only open and close the valve but, when correctly designed and adjusted, can create a 'physiological' closing pressure gradient across the valve.
This technique was first developed by Black (1973) and later modified by Martin et al. (1980) .
As with hydrodynamic testing, the 'value of accelerated fatigue testing is dependent not only on the design of the test equipment and experimental procedures, but also on the careful interpretation of the results. For example, Saul et al. (1981) , in their fatigue tests, Figure 6 . The Sheffield multivalve accelerated fatigue tester described leaflet abrasion due to contact with the cloth covering of the valve frame as being a common in vitro failure mode which was rarely, if ever, found in explanted clinical valves. This failure mode occurred because the cloth had not been infiltrated by a tissue ingrowth which rapidly occurs in vivo, providing a less abrasive surface, combined with the additional in vivo protection provided by the film of fibrin which forms on the leaflets.
Whilst in vitro accelerated fatigue testing can separate some of the influences of mechanical and biological factors on valve durability, it does not distinguish easily amongst the effects of tissue selection and treatment, leaflet geometry, frame design and technique of construction. Some of these latter effects can be isolated by extensive laboratory evaluation of all the materials used in the construction of a valve. Carefully controlled tissue selection procedures and a thorough investigation of the mechanical properties of the chemicallytreated material are essential prerequisites to the successful development of a tissue valve.
Glutaraldehyde, as noted by Woodroof (1979) , has been used routinely to stabilize connective tissue for heart valve substitutes over the past twelve years. The thermal stability of treated connective tissue can be assessed in the laboratory by observing the change in length of a sample as the temperature of a surrounding aqueous solution is slowly increased. A dramatic shortening of sample length occurs at the critical 'heat shrink temperature'. High values of this critical temperature correspond to greater stability of the tissue.
.Chemical modification of the tissue by different treatments will produce changes in its internal structure, usually by increasing the number of collagen cross-links. Since the mechanical properties of the tissue are intimately related to its structure, the effects of these treatments will be reflected in a change in the mechanical properties. Thus, measurement of the stress/strain response of the treated tissue will not only provide information on its mechanical strength, but will also give useful data concerning the efficacy of any particular treatment. In general terms, increased mechanical strength with minimum loss of flexibility, should enhance tissue leaflet durability.
Any material which is to be used in a heart valve substitute must have a good fatigue life since it will be required to withstand around forty million stress cycles per year for many years. This is equally as important for mechanical valves as it is for tissue valves. Although instances of mechanical valve failure are now relatively uncommon, they are not unheard of, and will almost always be catastrophic, as in the case of a strut fracture in a Bjork-Shiley valve reported by Brubakk et al. (1981) .
In vitro testing of prosthetic heart valves is now a popular topic in many engineering laboratories. If the investigations are carried out in collaboration with experienced cardiac surgeons then there is every likelihood that the interpretation of the test results will be beneficial to future valve development. However, if there is no clinical input to the research, the work may be good in scientific terms but not immediately relevant to in vivo applications. This latter situation can also lead to the incorrect extrapolation orin vitro data to predict the in vivo performance of a heart valve substitute.
Summary and future developments This paper has outlined the major events and developments which have occurred in the field of heart valve replacement since its inception some thirty years ago. Clearly, it has not been possible to include references to all aspects of what has been a remarkably extensive field of endeavour involving many individuals and research centres. Neither has it been practicable to include details of all the currently-used heart valve substitutes. The omission of any particular prosthesis should not be taken to imply that it is either unworthy or unacceptable.
Initially, the subject was very much the province of the cardiac surgeon. However, the increasing complexity of valve development has resulted in the involvement of scientists from many different disciplines. It is unlikely that any new prosthesis could reach the stage of routine clinical use today without the support of a multidisciplinary research team.
In an earlier section, attention was drawn to the advantages and disadvantages of the two major categories of heart valve substitutes. It does not seem likely that there will be any substantial improvements to mechanical valves in the immediate future. Minor changes of design and materials of construction will produce only marginal gains in performance for these valves. However, in the case of tissue valves there is a much greater opportunity for further developments and improved designs. In the former category, a better understanding and analysis of the effects of tissue treatments should lead to greater long-term reliability. It is also possible that researchers in the field of polymer science may yet develop a genuinely biocompatible man-made membrane of adequate strength, which could be used for the flexible leaflet prosthesis. From the point of view of design, newly developed techniques for analysing the stresses in tissue valve leaflets under load, should enable the development of geometrical configurations which result in minimum stress levels during function. This in turn will assist in increasing the long-term durability of the valves.
Even without improvements to the actual prostheses, there are many other facets to heart valve substitutes which require attention. At the present time there is no agreed standard of presentation of data for the various commercially-available valve models. For example, one of the most important and obvious items of information on any valve is its size in terms of its matching tissue annulus. Analysis of mechanical valve data from the Multicentre Valve Trial indicating the frequency of different valve sizes, as quoted by the manufacturers, is shown in Figure 7A . If these data are then converted to the actual tissue annulus diameters corresponding to each implantation, the frequency distribution is considerably altered, as shown in Figure 78 . This situation obtains because manufacturers can define their valves by either orifice or tissue annulus diameter, or even, as in some cases, by the 'sewing diameter'.
These differences in data can lead not only to confusion in the operating theatre, but also add to the difficulties encountered when making comparative in vitro evaluations of different valves. The only way to overcome these and other inconsistencies in the valve field is by the introduction of a 'Standard' which should include: (I) a universally agreed terminology;
(2) minimum requirements regarding properties of construction materials and standards of quality control;
(3) protocols for in vitro assessment, including upper and lower limits for haemodynamic performance and fatigue testing; (4) guidelines for the presentation of results of laboratory tests; (5) protocols for minimum animal trial requirements; and (6) acceptable methods of packaging and labelling, including consistent presentation of data. The advantages of such a 'Standard' would be to: (1) protect the consumer; and (2) assist the manufacturer to produce goods of adequate quality. The ultimate consumer is, of course, the patient. However, initially the surgeon is the user, and such a 'Standard' would provide him with the knowledge that any approved heart valve substitute has met clearly-defined specifications of construction, durability and performance. From the manufacturers' point of view, the 'Standard' would provide a guide to the production of a good product.
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As already noted, there is, as yet, no, ideal or optimum heart valve substitute. Consequently the search for improved designs will continue, as will the need for good , clinical assessment through long-term follow up of individual patients. In this context the value of multicentre' valve trials of the type referred to in this paper should be recognized.
